1 |
Zhang J, Zeng Q, Zhang P, Chen Y, Cao J. Efficacy evaluation and prognostic risk factors analysis of precise hepatectomy in the treatment of intermediate and advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2023;35:120-6. [PMID: 36468576 DOI: 10.1097/MEG.0000000000002460] [Reference Citation Analysis]
|
2 |
Khanam A, Kottilil S. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter? Int J Mol Sci 2022;24. [PMID: 36613878 DOI: 10.3390/ijms24010437] [Reference Citation Analysis]
|
3 |
Abid F, Iqbal T, Khan K, Badshah Y, Trembley JH, Ashraf NM, Shabbir M, Afsar T, Almajwal A, Razak S. Analyzing PKC Gamma (+ 19,506 A/G) polymorphism as a promising genetic marker for HCV-induced hepatocellular carcinoma. Biomark Res 2022;10:87. [PMID: 36451234 DOI: 10.1186/s40364-022-00437-6] [Reference Citation Analysis]
|
4 |
Gong D, Li S, Yu Z, Wang K, Qiao X, Wu C. Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population. BMC Med Genomics 2022;15:248. [PMID: 36447249 DOI: 10.1186/s12920-022-01394-7] [Reference Citation Analysis]
|
5 |
Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
|
6 |
Qiu X, Gao F, Wang K, Zhang Z, Shao C, Xu X. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment? iLIVER 2022;1:55-64. [DOI: 10.1016/j.iliver.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|